Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

PURPOSE: A novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab [Single Tremelimumab Regular Interval Durvalumab (STRIDE)] has demonstrated a favorable benefit-risk profile in the phase I/II Study 22 (NCT02519348) and phase III HIMALAYA study (NCT03298451). This study eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xuyang, Kelley, Robin Kate, Khan, Anis A., Standifer, Nathan, Zhou, Diansong, Lim, KyoungSoo, Krishna, Rajesh, Liu, Lu, Wang, Kun, McCoon, Patricia, Negro, Alejandra, He, Philip, Gibbs, Megan, Kurland, John F., Abou-Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932581/
https://www.ncbi.nlm.nih.gov/pubmed/36477555
http://dx.doi.org/10.1158/1078-0432.CCR-22-1983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932581/
https://www.ncbi.nlm.nih.gov/pubmed/36477555
http://dx.doi.org/10.1158/1078-0432.CCR-22-1983

Ejemplares similares